Week In Review: Beijing's BeiGene Raises $185 Million For Clinical Trial Program

Published: Nov 28, 2016

BeiGene completed a $200 secondary offering (including $15 million from selling shareholders) that will support global clinical trials of four novel drugs; Taikang Insurance paid $169 million to acquire 26% of China hospital operator Harmonicare; Shenzhen Hepalink invested $36.5 million in Kymab, a British novel mAb company; Beijing Tinavi Medical paid $1.5 million for China rights to spinal implants from France's Spineway; WuXi Biologics signed an MOU to create a manufacturing partnership with Prima Biomed of Australia for Prima's oncology drug candidate; Elanix Biotech of Germany and Oxford MEStar announced a LOI for a JV to market Elanix's GynRepair in China; and Yisheng Biopharma of Beijing completed a Phase I trial of its novel PIKA hepatitis B vaccine.

Back to news